Twin Tree Management’s Apogee Therapeutics APGE Stock Holding History

Twin Tree Management’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,295	Closed	-$297K	–	1379
2026 Q1	$277K	Buy	+3,295	New	+$239K	0.01%	1037

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Twin Tree Management's APGE Position: Q2 2026 in Review

Twin Tree Management sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 3,295 shares — an estimated $297K sold.

Twin Tree Management first reported a position in APGE in Q1 2026 and held it in 1 quarter. The position peaked at $277K in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Twin Tree Management reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
Twin Tree Management sold 3,295 Apogee Therapeutics shares in Q2 2026, an estimated $297K.
Twin Tree Management first reported a position in Apogee Therapeutics in Q1 2026 and held it in 1 quarter.
Twin Tree Management's Apogee Therapeutics position peaked at $277K in Q1 2026.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Twin Tree Management's 13F filing for Q2 2026, filed 12 Aug 2026.